A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease

Trial Profile

A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs BI 409306 (Primary) ; Donepezil
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim; Unilfarma
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Mar 2017 Planned number of patients changed from 655 to 295.
    • 29 Sep 2016 Planned number of patients changed from 500 to 655.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top